Clinical effects of HC 20-511 (ketotifen) in bronchial asthma and its inhibitory effect on antigen-induced morphological changes of basophils.
Sixty-four patients with confirmed bronchial asthma were treated with HC 20-511 (Ketotifen). HC20-511 was evaluated to be very effective in 6.3%, effective in 50.0% and slightly effective in 10.9% of these patients. The appearance of reactive basophils was inhibited by HC 20-511 in 5 out of 6 cases of reaction to house dust, in all three cases with buckwheat allergy to their allergen and in 7 out of 11 cases to anti-IgE. These results confirm that HC 20-511 inhibits type I allergic reactions induced by specific allergen and IgE.
D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000276:immunology; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D001491:Basophils / Q000276:immunology / Q000473:pathology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007665:Ketotifen; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D000485:Allergens; D010880:Piperidines; D013876:Thiophenes; D007073:Immunoglobulin E; D007665:Ketotifen